Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis

被引:2
作者
Tang, Lingrong [1 ]
Liu, Tingting [2 ]
Chen, Jun [3 ]
Dang, Jun [1 ]
Li, Guang [1 ]
机构
[1] China Med Univ, Dept Radiat Oncol, Hosp 1, Shenyang, Peoples R China
[2] Anshan Canc Hosp, Dept Radiat Oncol, Anshan, Peoples R China
[3] Shenyang Chest Hosp, Dept Radiat Oncol, Shenyang, Peoples R China
关键词
head and neck squamous cell carcinoma; HPV status; immune-checkpoint inhibitor; network meta-analysis; PD-L1; expression; recurrent or metastatic; standard of care; targeted therapy; SQUAMOUS-CELL CARCINOMA; METASTATIC HEAD; OPEN-LABEL; PHASE-III; RECURRENT; METHOTREXATE; GEFITINIB; GENERATION; NIVOLUMAB; DOCETAXEL;
D O I
10.2217/imt-2020-0070
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim: We assessed the efficiency of immune checkpoint inhibitors relative to other systemic therapies in previously treated recurrent/metastatic head and neck cancer. Materials & methods: Relative treatment effects were assessed from eligible randomized controlled trials using Bayesian network meta-analyses. Results: Among 15 trials evaluating 14 treatments, nivolumab achieved the best overall survival (OS) benefit; zalutumumab and buparlisib + paclitaxel provided the best progression-free survival benefit and objective response rate. Buparlisib + paclitaxel and zalutumumab were associated with the best OS rate at 6 and 12 months, respectively; nivolumab yielded the best OS rate at 18-24 months. Conclusion: Nivolumab was the most favorable treatment. Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments.
引用
收藏
页码:541 / 555
页数:15
相关论文
共 33 条
[1]   How to obtain the P value from a confidence interval [J].
Altman, Douglas G. ;
Bland, J. Martin .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[2]   Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial [J].
Argiris, Athanassios ;
Ghebremichael, Musie ;
Gilbert, Jill ;
Lee, Ju-Whei ;
Sachidanandam, Kamakshi ;
Kolesar, Jill M. ;
Burtness, Barbara ;
Forastiere, Arlene A. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1405-1414
[3]   General methods for monitoring convergence of iterative simulations [J].
Brooks, SP ;
Gelman, A .
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, 1998, 7 (04) :434-455
[4]   Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].
Burtness, Barbara ;
Harrington, Kevin J. ;
Greil, Richard ;
Soulieres, Denis ;
Tahara, Makoto ;
de Castro, Gilberto, Jr. ;
Psyrri, Amanda ;
Baste, Neus ;
Neupane, Prakash ;
Bratland, Ase ;
Fuereder, Thorsten ;
Hughes, Brett G. M. ;
Mesia, Ricard ;
Ngamphaiboon, Nuttapong ;
Rordorf, Tamara ;
Ishak, Wan Zamaniah Wan ;
Hong, Ruey-Long ;
Mendoza, Rene Gonzalez ;
Roy, Ananya ;
Zhang, Yayan ;
Gumuscu, Burak ;
Cheng, Jonathan D. ;
Jin, Fan ;
Rischin, Danny .
LANCET, 2019, 394 (10212) :1915-1928
[5]   Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J].
Cohen, Ezra E. W. ;
Soulieres, Denis ;
Le Tourneau, Christophe ;
Dinis, Jose ;
Licitra, Lisa ;
Ahn, Myung-Ju ;
Soria, Ainara ;
Machiels, Jean-Pascal ;
Mach, Nicolas ;
Mehra, Ranee ;
Burtness, Barbara ;
Zhang, Pingye ;
Cheng, Jonathan ;
Swaby, Ramona F. ;
Harrington, Kevin J. .
LANCET, 2019, 393 (10167) :156-167
[6]   Checking consistency in mixed treatment comparison meta-analysis [J].
Dias, S. ;
Welton, N. J. ;
Caldwell, D. M. ;
Ades, A. E. .
STATISTICS IN MEDICINE, 2010, 29 (7-8) :932-944
[7]  
Dias S., 2014, NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials Internet
[8]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[9]   Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) [J].
Fayette, Jerome ;
Wirth, Lori ;
Oprean, Cristina ;
Udrea, Anghel ;
Jimeno, Antonio ;
Rischin, Danny ;
Nutting, Christopher ;
Harari, Paul M. ;
Csoszi, Tibor ;
Cernea, Dana ;
O'Brien, Paul ;
Hanley, William D. ;
Kapp, Amy V. ;
Anderson, Maria ;
Penuel, Elicia ;
McCall, Bruce ;
Pirzkall, Andrea ;
Vermorken, Jan B. .
FRONTIERS IN ONCOLOGY, 2016, 6
[10]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386